- Home
- ESEA vs RIGL Comparison
ESEA vs RIGL Comparison
Compare ESEA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESEA
- RIGL
- Stock Information
- Founded
- ESEA 2005
- RIGL 1996
- Country
- ESEA Greece
- RIGL United States
- Employees
- ESEA N/A
- RIGL N/A
- Industry
- ESEA Marine Transportation
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ESEA Consumer Discretionary
- RIGL Health Care
- Exchange
- ESEA Nasdaq
- RIGL Nasdaq
- Market Cap
- ESEA 293.8M
- RIGL 247.1M
- IPO Year
- ESEA 2006
- RIGL 2000
- Fundamental
- Price
- ESEA $42.77
- RIGL $24.10
- Analyst Decision
- ESEA Buy
- RIGL Buy
- Analyst Count
- ESEA 1
- RIGL 5
- Target Price
- ESEA $53.00
- RIGL $31.30
- AVG Volume (30 Days)
- ESEA 35.7K
- RIGL 276.8K
- Earning Date
- ESEA 11-20-2024
- RIGL 11-07-2024
- Dividend Yield
- ESEA 5.61%
- RIGL N/A
- EPS Growth
- ESEA 16.05
- RIGL N/A
- EPS
- ESEA 16.98
- RIGL 0.22
- Revenue
- ESEA $205,168,137.00
- RIGL $157,374,000.00
- Revenue This Year
- ESEA $13.42
- RIGL $38.26
- Revenue Next Year
- ESEA $4.22
- RIGL $24.21
- P/E Ratio
- ESEA $2.52
- RIGL $108.84
- Revenue Growth
- ESEA 14.96
- RIGL 21.65
- 52 Week Low
- ESEA $26.20
- RIGL $7.48
- 52 Week High
- ESEA $50.92
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- ESEA 53.34
- RIGL 69.60
- Support Level
- ESEA $39.67
- RIGL $13.91
- Resistance Level
- ESEA $41.91
- RIGL $29.16
- Average True Range (ATR)
- ESEA 1.30
- RIGL 1.98
- MACD
- ESEA 0.21
- RIGL 1.23
- Stochastic Oscillator
- ESEA 93.09
- RIGL 64.80
About ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.